#USA #CINVANTI #Heron Therapeutics #Cary, North Carolina #ZYNRELEF

Heron Therapeutics Financial Results for 2024

Heron Therapeutics, Inc. (Nasdaq: HRTX) recently released its financial performance for the fourth quarter and the entirety of 2024, revealing a productive year that sets the stage for future growth. Noteworthy achievements include a GAAP net income of $3.6 million for the last quarter and an overall net revenue of $144.2 million for the entire year, reflecting a 14% increase year-over-year.

According to Craig Collard, the Chief Executive Officer of Heron, 2024 marked a significant milestone for the company. "We accomplished robust financial results and successfully met our operational targets, positioning ourselves for continued growth as we transition into 2025," Collard commented. This positive trajectory was endorsed by the launch of ZYNRELEF's Vial Access Needle (VAN), expected to enhance patient care and streamline usage in surgical settings.

Key Financial Highlights

The fourth quarter alone generated $8.5 million in net revenue from ZYNRELEF, which displays a crucial uptick in demand and adoption in its market space. Overall, Heron reported an adjusted EBITDA of $8.6 million for the full year, emphasizing its ability to maintain operational efficiency while expanding its product offerings. Cash and cash equivalents stood at $59.3 million at year-end, reinforcing the company's financial stability.

Earnings Breakdown

In terms of net revenue from key products:

• - Acute Care: Revenue surged by 57% to $30.1 million compared to the previous year.
• - APONVIE: Generated $4.5 million, marking a 224.8% rise.
• - ZYNRELEF: Achieved $25.5 million, which represents a 44.1% year-over-year increase.
• - Oncology Segment: Contributed $114.3 million, a 5.8% improvement.

Business Developments

Among the pivotal developments in 2024 was a favorable court ruling regarding patents for CINVANTI, which are valid until 2035, securing Heron's competitiveness in the oncology market. The partnership with Crosslink Network also significantly enhances the promotional effort for ZYNRELEF, particularly in orthopedic surgeries for post-operative pain, tapping into approximately 17 million targeted procedures annually.

ZYNRELEF's expanded label indications, approved by the FDA, bolster its versatility for various surgical procedures, extending its relevance and appeal to healthcare providers. These advancements are designed to encourage broader formulary acceptance and utilization in medical practices.

Future Guidance

Looking ahead, Heron projects full-year net revenue for 2025 to be between $153 million and $163 million along with adjusted EBITDA ranging from $0 to $8 million. This optimistic outlook stems from several key factors, including the separate payment status for ZYNRELEF, effective until at least the end of 2027, allowing for sustained financial support from government reimbursement programs.

The anticipated growth from ZYNRELEF is poised to be transformative, especially given the recent FDA approvals and expanded market opportunities. The company aims to capitalize on these dynamics as it cultivates its relationship with healthcare professionals and institutions.

Conference Call Details

Heron Therapeutics will host an earnings call, accessible via a registration link on their Investor Relations page, scheduled for February 27, 2025. This event will provide further insights into the company’s performance and strategic plans for the upcoming year.

Conclusion

As Heron Therapeutics progresses into 2025, it aligns its objectives and product offerings to meet the evolving demands of healthcare providers and patients alike. The company is not only fortified by its financial performance in 2024 but also by a strategic roadmap that includes innovative product launches and expanded market impacts, setting a strong foundation for continued success in the biotechnology realm.